These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 18171434

  • 1. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs.
    Efendic S, Alvarsson M, Brismar K, Wagner H.
    Acta Physiol (Oxf); 2008 Jan; 192(1):117-25. PubMed ID: 18171434
    [Abstract] [Full Text] [Related]

  • 2. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 4. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK.
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [Abstract] [Full Text] [Related]

  • 5. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T, Moritoh Y, Kataoka O, Suzuki N, Takeuchi K, Odaka H.
    Life Sci; 2009 Jul 17; 85(3-4):122-6. PubMed ID: 19427871
    [Abstract] [Full Text] [Related]

  • 6. [What can be expected from the GLP-1 agonists and DPP-4 inhibitors in the treatment of type 2 diabetes?].
    Egli M, Ruiz J.
    Rev Med Suisse; 2007 Jun 06; 3(114):1449-50, 1453-5. PubMed ID: 17639666
    [Abstract] [Full Text] [Related]

  • 7. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A.
    Diabetes Metab Res Rev; 2012 Dec 06; 28 Suppl 2():21-5. PubMed ID: 23280862
    [Abstract] [Full Text] [Related]

  • 8. Exploring the pharmacotherapeutic options for treating type 2 diabetes.
    Kruger DF.
    Diabetes Educ; 2008 Dec 06; 34 Suppl 3():60S-65S. PubMed ID: 18525066
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
    Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, Flatt PR, Bell PM.
    Diabet Med; 2005 May 06; 22(5):654-7. PubMed ID: 15842525
    [Abstract] [Full Text] [Related]

  • 10. [Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes].
    Scheen AJ, Radermecker RP, Philips JC, Paquot N.
    Rev Med Suisse; 2007 Aug 29; 3(122):1884, 1886-8. PubMed ID: 17896662
    [Abstract] [Full Text] [Related]

  • 11. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.
    Eur J Pharmacol; 2008 Jul 07; 588(2-3):325-32. PubMed ID: 18499100
    [Abstract] [Full Text] [Related]

  • 12. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J.
    Consult Pharm; 2009 Jun 07; 24 Suppl B():11-7. PubMed ID: 19555131
    [Abstract] [Full Text] [Related]

  • 13. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL.
    Diabetes Educ; 2008 Jun 07; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [Abstract] [Full Text] [Related]

  • 14. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA.
    Acta Diabetol; 2008 Dec 07; 45(4):253-68. PubMed ID: 18766296
    [Abstract] [Full Text] [Related]

  • 15. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov 07; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 16. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar 07; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

  • 17. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P.
    Diabetes Obes Metab; 2008 Dec 07; 10(12):1167-77. PubMed ID: 18494804
    [Abstract] [Full Text] [Related]

  • 18. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK, Holst JJ, Vilsbøll T.
    IDrugs; 2008 Jul 07; 11(7):497-501. PubMed ID: 18600596
    [Abstract] [Full Text] [Related]

  • 19. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK.
    J Am Pharm Assoc (2003); 2009 Jul 07; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [Abstract] [Full Text] [Related]

  • 20. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun 07; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.